We empower people everywhere to live naturally healthier lives

Chris has been in the biotech industry for nearly 30 years as an executive in both business and R&D leadership roles for start-ups as well as large multinational companies. Career highlights include twenty years with Martek Biosciences (Columbia, Maryland) where he built Martek’s nascent Dietary Supplement & Pharma ingredient division to a thriving global business, and seven years with DSM Nutritional Products (Kaiseraugst, Switzerland) where he helped lead DSM’s omega-3 business global expansion. In addition to Martek and DSM, Chris was an executive leader at several other successful technology B2B and B2C startups where he drove rapid revenue growth. Prior to his many years in business leadership, Chris started his career in R&D which will bring unique insights as we continue to translate Nuritas’ transformative innovation into commercial success. He holds an M.S. in Biotechnology from the Johns Hopkins University.

Amanda joined Nuritas in 2024 as Chief Financial Officer, having spent the previous four years as CFO for a data technology company called LightBox.  Prior to that, she was the CFO for High Ridge Brands and also held strategy and corporate finance roles at large multinationals such as PepsiCo and medium sized private equity backed companies such as Edible Arrangements and Waterworks.  She began her career in investment banking.

She is an advisory board member for New York University’s Center for Sustainability. She graduated with honors from both Duke University with a bachelor of science degree in economics and New York University Stern School of Business with a masters of business administration.

John Casey, has over 30 years of experience in the food and healthcare industry with unique expertise in manufacturing and supply chain, John is a worldwide expert in protein hydrolysates. He began his career in Abbott Infant Nutritional’s, and since then he has worked in various supply chain and manufacturing roles with Wyeth Infant Nutritional’s (now Nestle Infant Nutritional’s) and GE Healthcare. Most recently, he held the position of Vice President of Operations and Supply Chain for Kerry Group’s Applied Health and Nutrition division. John will be overseeing the proprietary manufacturing process at Nuritas.

Dr. Franklyn-Miller, a highly accomplished physician and with expertise in physiology, clinical design, and science communication. He has a Ph.D. in Biomechanics and served in the Royal Navy and Royal Marines for 16 years. Dr. Franklyn-Miller has extensive experience in working with high-profile sports teams and elite performers and has published more than 60 peer-reviewed papers. He is an editor of the British Journal of Sports Medicine and has authored a textbook and an IOC Handbook. With his expertise in machine learning, clinical trials, and end user analysis, he will oversee several departments at Nuritas, including software engineering, data curation, data science, proteomics, lab, and regulatory departments.

Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.

Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.

Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.

Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.

Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.

Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.

Alan is a distinguished professional who possesses a combination of scientific expertise and business acumen. He obtained a Master’s degree in Chemistry from Oxford University and a Ph.D. in Organic Chemistry from Harvard, which provided him with an in-depth understanding of the field. Currently based in the USA, Alan has established a remarkable career in the specialty materials industry, where he has excelled in both the corporate and venture worlds. He has a proven track record of successfully growing the revenue and valuation of companies he has worked for, and his expertise in taking new technologies to market has been instrumental in his achievements. Alan has a profound understanding of the scientific and commercial aspects of products and the processes involved in their commercialization.

Randall has assisted companies in accessing capital as founder of Exodus Commercial Capital and has served as its President since 2013. He has over 30 years of finance and operations experience that includes Fortune 50 companies such as GE Capital, Wells Fargo and Anthem. Randall has held various executive leadership roles, including: Executive Vice President and Chief Compliance Officer, Executive Vice President and Chief Auditor and Managing Director of Corporate Development. His experience includes the closing of several mergers and acquisitions for over $2B. He also served as CEO for a start-up logistics firm, s2f worldwide, LLC; that was sold to a Fortune 500 company.

He obtained his Bachelor of Science degree in General Management/Accounting and MBA in Finance from Purdue University.

Matthieu has over 25 years of experience in investment management with a focus on Asian regions. Matthieu’s investment experience has been centred primarily on thematic investing where he has successfully identified specific themes and designed strategies to profit from them. In mid-2012, Matthieu started to explore the imbalance created by China in the world market of animal protein. He quickly became convinced that it was the tipping point of a multi-decade investment opportunity. In late 2013-early 2014, Matthieu decided to concentrate solely on this and founded New Protein Capital (NPC). The scope of investment of NPC has since been expanded to include the multiple challenges of the food and feed production processes.

Prior to founding NPC in 2014, Matthieu was with Everest Capital, a large independent investment firm with offices in the US and in Singapore, for over 16 years. At Everest Capital, he was a Senior Managing Director and the Director of Research as well as a member of the Executive and Investment committees. Prior to Everest, Matthieu was with Banque Paribas, in Hong Kong, New York, Taipei and Paris.

Matthieu has a postgraduate degree in Corporate Finance from Université Paris Dauphine and has a graduate degree from Institut d’Etudes Politiques de Paris (Sciences Po).

Nora is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics. Nora’s research has focused primarily on protein evolution and comparative genomics.

Some of Nora’s publications have been placed in a library of the top 2% of published articles in the fields of biology and medicine.

Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms.

Previous to Nuritas™, Nora was the first scientist to show gene transfer between multi-cellular species. This ground-breaking find put into question many of the phylogenetic methods currently in use today.

Nora has developed a multitude of innovative software throughout her research career that are used to this day by research institutes and companies in over 70 countries. Nora has led international research teams around the world, in both academic and industrial settings, and has a proven record in new health-benefiting molecule discovery and commercialisation.

Over the next few years, Nora plans to lead the Nuritas™ team in their goal of reaching billions of people with their life-changing ingredients.

Joerg is a career veteran of the consumer and animal health arena having spent over 40 years at Bayer. During his tenure with Consumer Health he held positions as commercial head where he oversaw all sales and marketing activities in the EU, Asia-Pacific, as well as Latin America, and was responsible for over €3 billion in annual revenues as well as the acquisition of a plant-based OTC company. Joerg was an executive board member of the consumer health division and lead the go-to-market council on worldwide activities.

William W. Li, MD, is a world-renowned physician, scientist, speaker, and author of ‘Eat To Beat Disease – The New Science of How Your Body Can Heal Itself’. He is best known for leading the Angiogenesis Foundation. His ground-breaking work has impacted more than 70 diseases including cancer, diabetes, blindness, heart disease, and obesity. His TED Talk, “Can We Eat to Starve Cancer?” has garnered more than 11 million views, and he has appeared on: Good Morning America, CNN, MSNBC, NPR, Voice of America; and in The Atlantic, TIME, and The New York Times. An author of over 100 scientific publications in leading journals such as Science, the New England Journal of Medicine, and The Lancet, Dr. Li has served on the faculties of Harvard Medical School, Tufts University, and Dartmouth Medical School.

Currently a Board Member at Amazon, Mrs. Nooyi was the former Chief Executive Officer of PepsiCo, Inc., from October 2006 to October 2018, where she also served as the Chairman of its board of directors from May 2007 to February 2019. Having joined PepsiCo. in 1994, she held numerous positions including Chief Financial Officer as well as roles in corporate strategy and development and strategic planning. She has been regularly listed among the World’s 100 most influential women.

Throughout his illustrious, 40-year research career, Prof. German’s pivotal research has focused on improving foods and their ability to positively impact on health, using milk as the genetic blueprint for how foods can support health. During his career, he has been named to the Most Highly Cited Scientists List by ISI Index and has received honours including the President’s Award Canadian Federation of Biological Societies, John E Kinsella endowed chair University of California and Mention D’Honneur Du Jury ACADEMI MORIM.